TY - JOUR
T1 - Objectively Measured Chronic Lung Injury on Chest CT
AU - COPDGene Investigators
AU - Harmouche, Rola
AU - Ash, Samuel Y.
AU - Putman, Rachel K.
AU - Hunninghake, Gary M.
AU - San Jose Estepar, Ruben
AU - Martinez, Fernando J.
AU - Choi, Augustine M.
AU - Lynch, David A.
AU - Hatabu, Hiroto
AU - Han, Mei Lan K.
AU - Bowler, Russell P.
AU - Kalhan, Ravi
AU - Rosas, Ivan O.
AU - Washko, George R.
AU - San Jose Estepar, Raul
N1 - Funding Information:
FUNDING/SUPPORT: The COPDGene study [Grant NCT00608764] is supported by National Heart, Lung, and Blood Institute [Grants R01 HL089897 and R01 HL089856] as well as by the COPD Foundation through contributions made to an Industry Advisory Board comprising AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. Additional funding for this work includes National Institutes of Health [Grants T32-HL007633 and K08-HL145118 to Dr Ash; R01-HL107246 to Drs Washko, Raul San Jose Estepar, Harmouche; R01-HL116931 (Drs Raul San Jose Estepar and Washko); R01-HL116933 (Drs Washko, Raul San Jose Estepar, and Harmouche); R21-HL140422 (Drs San Jose Estepar and Washko); R01-HL111024 (Dr Hunninghake); P01-HL114501 (Drs Choi, Rosas, and Washko); and R01-HL089856 (Drs Washko, Lynch, and Raul San Jose Estepar). Additional funding was received from Boehringer Ingelheim Pharmaceuticals, Inc. (Dr Washko) and the Pulmonary Fibrosis Foundation (Dr Ash).Author contributions: S. Y. A. R. H. Raul. S. J. E. and G. R. W. contributed to the study concept and design as well as the statistical analysis. Raul S. J. E. and G. R. W. supervised the study. All authors contributed to the acquisition, analysis, or interpretation of data. All authors contributed to the drafting of the manuscript. Guarantor: R. H. S. Y. A. G. R. W. and Raul. S. J. E. take full responsibility for the content of this manuscript including the data and analysis. All authors contributed to the intellectual content. The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. Financial/nonfinancial disclosures: The authors have reported to CHEST the following: G. M. H. reports consulting for Medna LLC, Gerson Lehrman Group, and Patients Like Me, and is on a scientific advisory board for Genentech. F. J. M. reports grants from GlaxoSmithKline, during the conduct of the study; personal fees from Bayer, personal fees, nonfinancial support and other from Boehringer Ingelheim, nonfinancial support and other from Centocor, nonfinancial support from Gilead Sciences, personal fees from Genentech, personal fees from Ikaria, personal fees from Kadmon, personal fees from Nycomed/Takeda, personal fees from Pfizer, personal fees from Veracyte, personal fees from American Thoracic Society, personal fees from Academic CME, personal fees from Falco, personal fees from National Association for Continuing Education, personal fees from Axon Communication, personal fees from Johnson & Johnson, nonfinancial support from Biogen/Stromedix, grants from National Institutes of Health, personal fees from Clarion, personal fees from Continuing Education, personal fees from Potomac, personal fees from Afferent, personal fees from Adept, personal fees from Forest, personal fees from Janssen, personal fees from GlaxoSmithKline, personal fees from Nycomed/Takeda, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Ikaria/Bellerophon, personal fees from Genentech, personal fees from Novartis, personal fees from Pearl, personal fees from Pfizer, personal fees from Roche, personal fees from Sunovion, personal fees from Theravane, personal fees from Axon, personal fees from CME Incite, personal fees from California Society for Allergy and Clinical Immunology, personal fees from Annenberg, personal fees from Integritas, personal fees from InThought, personal fees from Miller Medical, personal fees from National Association for Continuing Education, personal fees from Paradigm, personal fees from Peer Voice, personal fees from UpToDate, personal fees from Haymarket Communications, personal fees from Western Society of Allergy and Immunology, personal fees from Informa, from Bioscale, personal fees from Unity Biotechnology, personal fees from ConCert, personal fees from Lucid, personal fees from Methodist Hospital, personal fees from Columbia University, personal fees from Prime, personal fees from WebMD, personal fees from PeerView Network, outside the submitted work. A. M. C. is a cofounder, stock holder and serves on the Scientific Advisory Board for Proterris, which develops therapeutic uses for carbon monoxide. A. M. C. also has a use patent on carbon monoxide. A. M. C. served as a consultant for Teva Pharmaceuticals in July 2018. D. A. L. reports grants from NHLBI, personal fees from Parexel, research support from Veracyte, personal fees from Boehringer Ingelheim, and personal fees from Genentech/Roche. H. H. reports grant funding from Aze Inc, grant funding from Canon Inc, grant funding from Toshiba Medical System Inc, and is on an advisory board for Toshiba Medical System Inc. G. R. W. reports other support from Genentech, GlaxoSmithKline, PulmonX, and Janssen. Raul. S. J. E. reports personal fees from Boehringer Ingelheim, Toshiba and Eolo Medical. None declared (R. H. S. Y. A. R. K. P. Ruben. S. J. E. M. K. H. R. P. B. R. K. I. O. R.). Role of the sponsor: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. *COPDGene Investigators: List of COPDGene Investigators can be found in the Supplemental Materials section of the online article. Additional information: The e-Appendix can be found in the Supplemental Materials section of the online article.
Funding Information:
FUNDING/SUPPORT: The COPDGene study [Grant NCT00608764 ] is supported by National Heart, Lung, and Blood Institute [Grants R01 HL089897 and R01 HL089856 ] as well as by the COPD Foundation through contributions made to an Industry Advisory Board comprising AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. Additional funding for this work includes National Institutes of Health [Grants T32-HL007633 and K08-HL145118 to Dr Ash; R01-HL107246 to Drs Washko, Raul San Jose Estepar, Harmouche; R01-HL116931 (Drs Raul San Jose Estepar and Washko); R01-HL116933 (Drs Washko, Raul San Jose Estepar, and Harmouche); R21-HL140422 (Drs San Jose Estepar and Washko); R01-HL111024 (Dr Hunninghake); P01-HL114501 (Drs Choi, Rosas, and Washko); and R01-HL089856 (Drs Washko, Lynch, and Raul San Jose Estepar). Additional funding was received from Boehringer Ingelheim Pharmaceuticals, Inc . (Dr Washko) and the Pulmonary Fibrosis Foundation (Dr Ash).
Publisher Copyright:
© 2019 American College of Chest Physicians
PY - 2019/12
Y1 - 2019/12
N2 - Background: Tobacco smoke exposure is associated with emphysema and pulmonary fibrosis, both of which are irreversible. We have developed a new objective CT analysis tool that combines densitometry with machine learning to detect high attenuation changes in visually normal appearing lung (NormHA) that may precede these diseases. Methods: We trained the classification tool by placing 34,528 training points in chest CT scans from 297 COPDGene participants. The tool was then used to classify lung tissue in 9,038 participants as normal, emphysema, fibrotic/interstitial, or NormHA. Associations between the quartile of NormHA and plasma-based biomarkers, clinical severity, and mortality were evaluated using Jonckheere-Terpstra, pairwise Wilcoxon rank-sum tests, and multivariable linear and Cox regression. Results: A higher percentage of lung occupied by NormHA was associated with higher C-reactive protein and intercellular adhesion molecule 1 (P for trend for both <.001). In analyses adjusted for multiple covariates, including high and low attenuation area, compared with those in the lowest quartile of NormHA, those in the highest quartile had a 6.50 absolute percent lower percent predicted lower FEV1 (P <.001), an 8.48 absolute percent lower percent predicted forced expiratory volume, a 10.78-meter shorter 6-min walk distance (P =.011), and a 56% higher risk of death (P =.003). These findings were present even in those individuals without visually defined interstitial lung abnormalities. Conclusions: A new class of NormHA on CT may represent a unique tissue class associated with adverse outcomes, independent of emphysema and fibrosis.
AB - Background: Tobacco smoke exposure is associated with emphysema and pulmonary fibrosis, both of which are irreversible. We have developed a new objective CT analysis tool that combines densitometry with machine learning to detect high attenuation changes in visually normal appearing lung (NormHA) that may precede these diseases. Methods: We trained the classification tool by placing 34,528 training points in chest CT scans from 297 COPDGene participants. The tool was then used to classify lung tissue in 9,038 participants as normal, emphysema, fibrotic/interstitial, or NormHA. Associations between the quartile of NormHA and plasma-based biomarkers, clinical severity, and mortality were evaluated using Jonckheere-Terpstra, pairwise Wilcoxon rank-sum tests, and multivariable linear and Cox regression. Results: A higher percentage of lung occupied by NormHA was associated with higher C-reactive protein and intercellular adhesion molecule 1 (P for trend for both <.001). In analyses adjusted for multiple covariates, including high and low attenuation area, compared with those in the lowest quartile of NormHA, those in the highest quartile had a 6.50 absolute percent lower percent predicted lower FEV1 (P <.001), an 8.48 absolute percent lower percent predicted forced expiratory volume, a 10.78-meter shorter 6-min walk distance (P =.011), and a 56% higher risk of death (P =.003). These findings were present even in those individuals without visually defined interstitial lung abnormalities. Conclusions: A new class of NormHA on CT may represent a unique tissue class associated with adverse outcomes, independent of emphysema and fibrosis.
KW - computed tomography
KW - emphysema
KW - lung injury
KW - pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85071853096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071853096&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2019.05.020
DO - 10.1016/j.chest.2019.05.020
M3 - Article
C2 - 31233744
AN - SCOPUS:85071853096
SN - 0012-3692
VL - 156
SP - 1149
EP - 1159
JO - CHEST
JF - CHEST
IS - 6
ER -